Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Inventory (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Inventory data on record, last reported at $45.3 million in Q3 2025.

  • For Q3 2025, Inventory fell 10.08% year-over-year to $45.3 million; the TTM value through Sep 2025 reached $45.3 million, down 10.08%, while the annual FY2024 figure was $50.1 million, 2.56% down from the prior year.
  • Inventory reached $45.3 million in Q3 2025 per MRVI's latest filing, down from $46.7 million in the prior quarter.
  • Across five years, Inventory topped out at $62.4 million in Q3 2022 and bottomed at $43.2 million in Q4 2022.
  • Average Inventory over 5 years is $51.1 million, with a median of $50.1 million recorded in 2024.
  • Peak YoY movement for Inventory: surged 54.82% in 2021, then decreased 21.28% in 2023.
  • A 5-year view of Inventory shows it stood at $51.6 million in 2021, then dropped by 16.3% to $43.2 million in 2022, then grew by 19.11% to $51.4 million in 2023, then fell by 2.56% to $50.1 million in 2024, then dropped by 9.5% to $45.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Inventory were $45.3 million in Q3 2025, $46.7 million in Q2 2025, and $49.8 million in Q1 2025.